Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
6/10
|
27.3 | 41.44 | -34.11% | 27.54 | -0.8728% |
| P/S |
|
1.57 | 20 | -92.13% |
|
|
| P/BV |
|
1.15 | 3.7 | -68.88% |
|
|
| P/FCF |
|
-36.76 | 80.43 | -145.7% |
|
|
| Ev/Ebitda |
|
12.93 | 16.62 | -22.23% |
|
|
| Ev/S |
|
1.92 | 23.5 | -91.81% |
|
|
| Ev/FCF |
|
-41.45 | 83.06 | -149.91% |
|
|
| E/P |
|
0.0338 | 0.0217 | 55.89% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
6/10
|
19.01 | -84.6 | -122.47% | 19.37 | -1.87% |
| ROE |
|
5.29 | 6.66 | -20.6% |
|
|
| ROA |
|
2.16 | 3.59 | -39.79% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
5.76 | -76.53 | -107.53% |
|
|
| ROCE |
|
0 | 1.78 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
3/10
|
3.91 | 0.7401 | 428.42% | 3.38 | +15.67% |
| Nеt Debt/Ebitda |
|
1.85 | -0.1073 | -1821.84% |
|
|
| Debt/Ratio |
|
0.2713 | 0.1017 | 166.65% |
|
|
| Debt/Equity |
|
0.8724 | 0.2121 | 311.29% |
|
|
| Debt/Net Income |
|
12.9 | 1.29 | 898.28% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.3991 | -100% | 1.06 | -100% |
| Number of years of dividend growth |
|
0 | 1 | -100% | ||
| DSI |
|
0.7143 | 0.6935 | 3% |
|
|
| Average dividend growth |
|
5.39 | 3.04 | 77.1% |
|
|
| Average percentage for 5 years |
|
1.06 | 1.4 | -24.21% |
|
|
| Average percentage for payments |
|
58.04 | 45.07 | 28.78% |
|
|
| Difference from average difference in sector |
|
-0.3991 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
6/10
|
44.83 | -94.63 | -147.37% | ||
| Growth impulse Ebitda in 5 years |
|
-13.61 | 12.85 | -205.91% | ||
| Growth impulse Net Income in 5 years |
|
-28.16 | -157.35 | -82.1% | ||
| Growth impulse FCF in 5 years |
|
159.92 | -361.32 | -144.26% | ||
| Growth impulse EPS in 5 years |
|
-31.31 | -109.66 | -71.45% |
IP Score
4.4/10
